natgillin/translations-raw huggingface dataset:
The main measure of effectiveness was how Eklira Genuair improved patients’ forced expiratory volumes (FEV1, the maximum volume of air a person can breathe out in one second) after six months.
Glavno merilo učinkovitosti je bilo izboljšanje forsiranega ekspiracijskega volumna (FEV1, največja količina zraka, ki jo oseba lahko izdihne v eni sekundi) po šestih mesecih uporabe zdravila Eklira Genuair.
The main measure of effectiveness was how far the patients could walk in six minutes (a way of measuring exercise capacity), but the study in class II disease also looked at the change in the resistance to blood flow in the lungs’ blood vessels (a marker of how narrow the blood vessels are).
Glavno merilo učinkovitosti je bila razdalja, ki jo je bolnik lahko prehodil v šestih minutah (način merjenja telesne zmogljivosti), v študiji bolezni II. funkcijskega razreda pa so proučevali tudi spremembo v uporu pretoka krvi v pljučnih žilah (parameter, ki pokaže, kako ozke so krvne žile).
The main measure of effectiveness was how far the patients could walk in six minutes (a way of measuring exercise capacity), but the study in class II disease also looked at the change in the resistance to blood flow in the lungs’ blood vessels (a marker of how narrow the blood vessels are).
Glavno merilo učinkovitosti je bila razdalja, ki so jo bolniki lahko prehodili v šestih minutah (metoda merjenja telesne zmogljivosti), v študiji pri bolnikih s pljučno arterijsko hipertenzijo razreda II pa so proučevali tudi spremembo upornosti proti toku krvi v pljučnih žilah (parameter, ki pokaže, kako ozke so krvne žile).
The main measure of effectiveness was how Hirobriz Breezhaler compared with placebo in improving patients’ forced expiratory volumes (FEV1) after 12 weeks.
Glavno merilo učinkovitosti je bilo izboljšanje forsiranega ekspiracijskega volumna v prvi sekundi (FEV1) po 12 tednih jemanja zdravila Hirobriz Breezhaler v primerjavi s placebom.
The main measure of effectiveness was how long it took before the patients had an episode of atrial fibrillation again or the change in the patients’ heart rate after two weeks.
Glavno merilo učinkovitosti je bil čas do ponovne atrijske fibrilacije ali sprememba srčnega utripa pri bolniku po dveh tednih.
The main measure of effectiveness was how long it took until the disease got worse or the patient died.
učinkovitosti je bil čas, v katerem se je bolniku bolezensko stanje poslabšalo, oziroma čas do smrti bolnika.
The main measure of effectiveness was how long it took until the disease got worse.
Glavno merilo učinkovitosti je bil čas do poslabšanja bolezni.
The main measure of effectiveness was how long it took until the patient’s symptoms were relieved.
Glavno merilo učinkovitosti je bil čas do olajšanja bolnikovih simptomov.
The main measure of effectiveness was how long it was before the patient’s disease flared up again.
Glavno merilo učinkovitosti je bil čas do ponovnega izbruha bolezni.
The main measure of effectiveness was how long patients could exercise after 12 weeks of treatment, compared with before treatment.
Glavno merilo učinkovitosti je bil čas, kako dolgo so lahko bolniki telovadili po 12- tedenskem zdravljenju, v primerjavi s časom pred zdravljenjem.
The main measure of effectiveness was how long the patients could exercise on a bicycle or a treadmill, measured at the start and the end of each study.
Glavno merilo učinkovitosti je bil čas, ko so bolniki zdržali pri vadbi na sobnem kolesu ali tekaški stezi, merjen na začetku in ob koncu vsake študije.
The main measure of effectiveness was how long the patients could exercise on a bicycle or a treadmill, measured at the start and the end of each study.
Glavno merilo učinkovitosti je bilo, koliko časa so bolniki zdržali pri vadbi na sobnem kolesu ali tekaški stezi, merjeno na začetku in ob koncu vsake študije.
The main measure of effectiveness was how long the patients lived without the disease getting worse.
Glavno merilo učinkovitosti je bil čas preživetja bolnikov brez poslabšanja bolezni.
The main measure of effectiveness was how long the patients spent in the ‘off’ or in the ‘on’ state.
Glavno merilo učinkovitosti je bil čas, ki ga je bolnik preživel v vključitvenem oziroma prekinitvenem obdobju.
The main measure of effectiveness was how many patients experienced a new ‘ischaemic event’ (heart attack, ischaemic stroke or death) over one to three years.
Glavno merilo učinkovitosti je bilo, koliko bolnikov je v enem do treh let imelo nov „ishemični dogodek“ (srčni napad, ishemično kap ali smrt).
The main measure of effectiveness was how many patients experienced a new ‘ischaemic event’ (heart attack, ischaemic stroke or death) over one to three years.
Glavno merilo učinkovitosti je bilo, koliko bolnikov je v enem do treh let utrpelo nov „ishemični dogodek“ (srčni napad, ishemično kap ali smrt).
The main measure of effectiveness was how much haemoglobin levels rose after 12 weeks of treatment.
Glavno merilo učinkovitosti je bil porast ravni hemoglobina po 12 tednih zdravljenja.
The main measure of effectiveness was how Onbrez Breezhaler compared with placebo in improving patients’ forced expiratory volumes (FEV1) after 12 weeks.
Glavno merilo učinkovitosti je bilo izboljšanje forsiranega ekspiracijskega volumna v prvi sekundi (FEV1) po 12 tednih jemanja zdravila Onbrez Breezhaler v primerjavi s placebom.
The main measure of effectiveness was how Oslif Breezhaler compared with placebo in improving patients’ forced expiratory volumes (FEV1) after 12 weeks.
Glavno merilo učinkovitosti je bilo izboljšanje forsiranega ekspiracijskega volumna v prvi sekundi (FEV1) po 12 tednih jemanja zdravila Oslif Breezhaler v primerjavi s placebom.
The main measure of effectiveness was how quickly the patients had pain relief after experiencing breakthrough pain.
Glavno merilo učinkovitosti je bila hitrost olajšanja bolečine pri bolnikih po nastopu prebijajoče bolečine.
The main measure of effectiveness was how the lowest IgG levels (called ‘trough levels’) seen during Hizentra treatment compared with the lowest levels seen during previous immunoglobulin treatment.
Glavno merilo učinkovitosti je bila vrednost najnižje ravni imunoglobulina (imenovana „najnižja koncentracija“), opažena pri zdravljenju z zdravilom Hizentra, v primerjavi z najnižjo ravnjo, opaženo pri predhodnih zdravljenjih z imunoglobulinom.
The main measure of effectiveness was improvement in control of diabetes 6 weeks after starting treatment, which was determined by improvement of blood sugar measurements and at least one of three clinical signs: bodyweight, polyuria and polydipsia.
Glavno merilo učinkovitosti je bilo izboljšanje nadzora nad sladkorno boleznijo 6 tednov po začetku zdravljenja, ki so ga opredelili kot izboljšanje izmerjenih vrednosti sladkorja v krvi in vsaj enega od treh kliničnih znakov: telesne mase, poliurije ali polidipsije.
The main measure of effectiveness was overall survival (how long the patients lived).
Glavno merilo učinkovitosti je bil skupni čas preživetja (kako dolgo so bolniki živeli).
The main measure of effectiveness was overall survival (the average length of time the patients lived).
Glavno merilo učinkovitosti je bilo skupno preživetje bolnikov (povprečni čas, kako dolgo so živeli).
The main measure of effectiveness was progression free survival (how long the patients lived without their disease getting worse).
Glavno merilo učinkovitosti je bilo preživetje brez napredovanja bolezni (čas, ki ga bolnik preživi brez poslabšanja bolezni).
The main measure of effectiveness was progression free survival (how long the patients lived without their disease getting worse).
Glavno merilo učinkovitosti je bilo preživetje brez napredovanja bolezni (čas, ki so ga bolniki preživeli brez poslabšanja bolezni).
The main measure of effectiveness was progression-free survival (how long a patient lived without the disease getting worse).
Glavno merilo učinkovitosti je bil čas preživetja bolnikov, med katerim bolezen ni napredovala (kako dolgo so bolniki živeli brez poslabšanja bolezni).
The main measure of effectiveness was progression-free survival (how long the patients lived without their disease getting worse).
Glavno merilo učinkovitosti je bil čas preživetja bolnikov, med katerim bolezen ni napredovala (čas preživetja, med katerim se bolezen ni poslabšala).
The main measure of effectiveness was progression-free survival.
Glavno merilo učinkovitosti je bil čas preživetja bolnikov, med katerim bolezen ni napredovala.
The main measure of effectiveness was reduction in mobility, posture and pain.
Glavna merila učinkovitosti so bil spremembe v gibljivosti, drži in bolečini.
The main measure of effectiveness was reduction in pain sensitivity and the study showed Metacam to have an effect in reducing pain associated with the dehorning procedure.
Glavno merilo učinkovitosti je bilo zmanjšanje občutljivosti za bolečino, študija pa je pokazala, da zdravilo Metacam učinkuje pri zmanjševanju bolečine, povezane z odstranjevanjem rogov.
The main measure of effectiveness was reduction of numbers of worm larvae in faeces at 28 days after single treatment.
Glavno merilo učinkovitosti je bilo število ličink črva v izločkih 28. dan po enkratnem zdravljenju.
The main measure of effectiveness was related to the change in symptoms such as pain associated with sexual activity as well as vaginal dryness using a validated questionnaire.
Glavno merilo učinkovitosti je bilo povezano s spremembo simptomov, kot sta bolečina med spolno aktivnostjo in suha nožnica, kar so ugotavljali s pomočjo potrjenega vprašalnika.
The main measure of effectiveness was the ability of the treatment to reduce heavy uterine bleeding.
Glavno merilo učinkovitosti je bila zmanjšana krvavitev iz maternice kot posledica zdravljenja.
The main measure of effectiveness was the ability to reduce proteinuria.
Glavno merilo učinkovitosti je bila sposobnost za zmanjševanje proteinurije.
The main measure of effectiveness was the average length of time before the patient’s disease got worse again (progression-free survival), which was 12 months in patients given Farydak, compared with around 8 months in those given placebo.
Glavno merilo učinkovitosti je bil povprečen čas do ponovnega poslabšanja bolezni (preživetje brez napredovanja), ki je bil 12 mesecev pri bolnikih, ki so prejemali zdravilo Farydak, in približno 8 mesecev pri bolnikih, ki so prejemali placebo.
The main measure of effectiveness was the average length of time that patients survived after treatment.
Glavno merilo učinkovitosti je bil povprečen čas preživetja bolnikov po zdravljenju.
The main measure of effectiveness was the change in BCVA over the period of the study.
Glavno merilo učinkovitosti je bila sprememba BCVA v času trajanja študije.
The main measure of effectiveness was the change in bone density (a measure of how strong the bones are) in the lumbar (lower) spine after a year of treatment.
Glavno merilo učinkovitosti je bila sprememba kostne gostote (merilo trdnosti kosti) v ledvenem (spodnjem) delu hrbtenice po enem letu zdravljenja.
The main measure of effectiveness was the change in bone density in the lumbar spine after a year of treatment.
Glavno merilo učinkovitosti je bila sprememba kostne gostote v ledvenem delu hrbtenice po letu dni zdravljenja.
The main measure of effectiveness was the change in bone density of the lumbar spine after two years.
Glavno merilo učinkovitosti je bila sprememba gostote kosti v ledvenem delu hrbtenice po dveh letih.
The main measure of effectiveness was the change in patients’ kidney function after 18 months of treatment.
Glavno merilo učinkovitosti je bila sprememba v delovanju ledvic bolnikov po 18 mesecih zdravljenja.
The main measure of effectiveness was the change in symptoms measured on a standard scale for schizophrenia after eight weeks; the study of maintenance treatment compared the effects of four doses of Zypadhera with those of olanzapine taken by mouth in 1,065 patients.
Glavno merilo učinkovitosti so bile spremembe v simptomih, ki so jih merili s standardno lestvico shizofrenije po osmih tednih; v študiji vzdrževalnega zdravljenja pri 1 065 bolnikih so primerjali učinke štirih odmerkov zdravila Zypadhera z učinki peroralno zaužitega olanzapina.
The main measure of effectiveness was the change in symptoms over 26 weeks, as assessed on a standard scale (Unified Parkinson’s Disease Rating Scale, UPDRS).
Glavno merilo učinkovitosti je bila sprememba simptomov po 26 tednih, ki je bila ocenjena s standardno lestvico (Enotno ocenjevalno lestvico Parkinsonove bolezni - Unified Parkinson’s Disease Rating Scale, UPDRS).
The main measure of effectiveness was the change in the amount of a substance in the blood called glycosylated haemoglobin (HbA1c) after six months or one year.
Glavno merilo učinkovitosti je bila sprememba količine snovi v krvi, imenovane glikozilirani hemoglobin (HbA1c), po šestih mesecih ali enem letu.
The main measure of effectiveness was the change in the blood level of ammonia after 4 weeks of treatment.
Glavno merilo učinkovitosti je bila sprememba v ravni amoniaka v krvi po štirih tednih zdravljenja.
The main measure of effectiveness was the change in the distance the patient could walk in six minutes after 48 weeks of treatment.
Glavno merilo učinkovitosti je bila sprememba razdalje, ki jo je bolnik po 48 tednih zdravljenja lahko prehodili v šestih minutah.
The main measure of effectiveness was the change in the distance the patients could walk in six minutes after 12 weeks of treatment.
Glavno merilo učinkovitosti je bila razdalja, ki so jo bolniki lahko prehodili v šestih minutah po 12 tednih zdravljenja.
The main measure of effectiveness was the change in the level of a substance in the blood called glycosylated haemoglobin (HbA1c), which gives an indication of how well the blood glucose is controlled, after 24 weeks of treatment.
Glavno merilo učinkovitosti je bila sprememba ravni snovi v krvi, ki se imenuje glikozilirani hemoglobin (HbA1c), kar označuje uspešnost urejenosti glukoze v krvi po 24 tednih zdravljenja.
The main measure of effectiveness was the change in the levels of HIV in the patients’ blood (viral load).
Glavno merilo učinkovitosti je bila sprememba koncentracije virusa HIV (virusnega bremena) v bolnikovi krvi.
The main measure of effectiveness was the change in the number of seizures after 11 to 12 weeks; for generalised anxiety disorder, there were eight studies involving over 3,000 patients.
Glavno merilo učinkovitosti je bila sprememba števila napadov po 11 do 12 tednih; v osmih študijah so proučevali generalizirano anksiozno motnjo pri več kot 3 000 bolnikih.
The main measure of effectiveness was the change in the patients’ symptoms of mania after six weeks on a standard scale.
Glavno merilo učinkovitosti je bila sprememba simptomov manije, merjenih po standardni lestvici, po šestih tednih zdravljenja.
The main measure of effectiveness was the change in the patients’ symptoms two hours after giving a dose of loxapine, assessed using a standard scale of agitation in patients with schizophrenia and bipolar disorder (positive and negative symptom scale, excited component: PEC score).
Glavno merilo učinkovitosti je bila sprememba bolnikovih simptomov dve uri po dajanju odmerka loksapina, ki so jo ocenili na podlagi standardne ocenjevalne lestvice agitacije pri bolnikih s shizofrenijo in bipolarno motnjo (lestvica pozitivnih in negativnih simptomov, komponenta razburjenosti: rezultat PEC).
The main measure of effectiveness was the change in the patients’ symptoms using a standard scale for schizophrenia after six weeks.
Glavno merilo učinkovitosti je bila sprememba bolnikovih simptomov po standardizirani lestvici za shizofrenijo po šestih tednih zdravljenja.
The main measure of effectiveness was the change in the patients’ ‘Young mania rating scale’ (Y-MRS) score.
Glavno merilo učinkovitosti je bila sprememba bolnikovih simptomov po ocenjevalni lestvici za manijo (Y-MRS).
The main measure of effectiveness was the change in the patient’s symptoms, measured using a standard scale for schizophrenia called ‘positive and negative syndrome scale’ (PANSS).
Glavno merilo učinkovitosti je bila sprememba bolnikovih simptomov, ki so jo izmerili s standardno lestvico za shizofrenijo, imenovano „lestvica pozitivnih in negativnih sindromov“ (positive and negative syndrome scale – PANSS).
The main measure of effectiveness was the change in the severity of Parkinson’s disease.
Glavno merilo učinkovitosti je bila sprememba resnosti Parkinsonove bolezni.
The main measure of effectiveness was the change in the severity of their pain during the 30 minutes after treatment.
Glavno merilo učinkovitosti je bila sprememba v jakosti bolečine v 30 minutah po zdravljenju.
The main measure of effectiveness was the change in the speed at which the patients made saccadic horizontal eye movements after a year, but the study also looked at other neurological symptoms such as the patients’ ability to swallow and their intellectual function.
Glavno merilo učinkovitosti je bila sprememba hitrosti, s katero je bolnik delal sunkovite vodoravne gibe z očmi po enem letu, v študiji pa so opazovali tudi druge nevrološke simptome, kot je bolnikova sposobnost požiranja in njegova intelektualna zmožnost.
The main measure of effectiveness was the change in the symptoms, joint damage and physical function after up to 54 weeks.
Glavno merilo učinkovitosti so bile spremembe v simptomih, poškodbah sklepov in fizičnih zmogljivosti po največ 54 tednih.
The main measure of effectiveness was the change in vision in the affected eye after a year of treatment, using a standard eye test with a letter chart.
Glavno merilo učinkovitosti je bila sprememba vida prizadetega očesa po enoletnem zdravljenju, pri čemer je bil uporabljen standardni očesni test s tabelo s črkovnimi znaki.
The main measure of effectiveness was the change in vision seen in the first 3 months of treatment, using a standard eye test with a letter chart.
Glavno merilo učinkovitosti je bila sprememba vida v prvih treh mesecih zdravljenja, pri čemer je bil uporabljen standardni očesni test s tabelo s črkovnimi znaki.
The main measure of effectiveness was the decrease in LDL-cholesterol levels after four to six weeks, except for one of the studies looking at Cholestagel taken on its own, which measured the cholesterol levels after six months.
Glavno merilo učinkovitosti je bilo znižanje ravni LDL- holesterola po štirih do šestih tednih, razen v študiji, v katerih so proučevali samostojno jemanje zdravila Cholestagel in so raven holesterola izmerili po šestih mesecih.
The main measure of effectiveness was the delay to progression of disability.
Glavno merilo učinkovitosti je bil odlog do napredovanja invalidnosti.
The main measure of effectiveness was the doctor’s assessment of how well bleeding was stopped.
Glavno merilo učinkovitosti je bila zdravnikova ocena uspešnosti zaustavitve krvavitve.
The main measure of effectiveness was the increase in haemoglobin.
Glavno merilo učinkovitosti je bilo povečanje ravni hemoglobina.
The main measure of effectiveness was the increase in platelets.
Glavno merilo učinkovitosti je bilo povečanje števila trombocitov.
The main measure of effectiveness was the length of time that patients lived without the disease getting worse.
Glavno merilo učinkovitosti je bil čas preživetja bolnikov brez poslabšanja bolezni.
The main measure of effectiveness was the length of time until the disease came back or the patient died.
Glavno merilo učinkovitosti je bil čas do ponovnega pojava bolezni ali smrti bolnika.
The main measure of effectiveness was the level of antibodies in the blood against the viruses in the vaccine.
Glavno merilo učinkovitosti je bila raven protiteles v krvi proti virusoma iz cepiva.
The main measure of effectiveness was the level of hepatitis C virus circulating in the blood before and after six months or a year of treatment, and at ‘follow-up’, six months later.
Glavno merilo učinkovitosti je bila raven hepatitisa C v krvi pred zdravljenjem, po šestih mesecih ali enem letu zdravljenja ter ob kontrolnem pregledu šest mesecev pozneje.
The main measure of effectiveness was the level of HIV in the blood (viral load) in the first 48 weeks of treatment.
Glavno merilo učinkovitosti je bila raven virusa HIV v krvi (virusno breme) v prvih 48 tednih zdravljenja.
The main measure of effectiveness was the number of patients in whom a target number of stem cells could be collected from the blood within two or four collection days.
Glavno merilo učinkovitosti je bilo število bolnikov, pri katerih so lahko zbrali ciljno število matičnih celic iz krvi v dveh do štirih zbiralnih dnevih.
The main measure of effectiveness was the number of patients in whom the transplant failed (as measured by looking at, for example, the need for a repeat transplant or a return to dialysis) after one year’s treatment.
Glavno merilo učinkovitosti je bilo število bolnikov, pri katerih se je presaditev po enoletnem zdravljenju izkazala za neuspešno (merilo je bila na primer potreba po ponovni presaditvi ali vrnitvi na dializo).
The main measure of effectiveness was the number of patients in whom treatment failed, defined as blood levels of hepatitis B immunoglobulins falling below 100 IU per litre or re- infection by hepatitis B virus during the 24 weeks of treatment.
Glavno merilo učinkovitosti je bilo število bolnikov, pri katerih zdravljenje ni bilo uspešno, tj. ravni imunoglobulina proti hepatitisu B v krvi so bile pod 100 i.e. na liter oziroma v 24 tednih zdravljenja je prišlo do ponovne okužbe z virusom hepatitisa B.
The main measure of effectiveness was the number of patients who did not have any nausea or vomiting over the five days after receiving chemotherapy.
Glavno merilo učinkovitosti je bilo število bolnikov, pri katerih se v petih dneh po kemoterapiji slabost in bruhanje nista pojavila.
The main measure of effectiveness was the number of patients who did not need a blood transfusion for at least 56 days in the first study and 182 days in the second study.
Glavno merilo učinkovitosti je bilo število bolnikov, ki transfuzije krvi niso potrebovali vsaj 56 dni v prvi in 182 dni v drugi študiji.
The main measure of effectiveness was the number of patients who had a PTH level below 250 micrograms per litre at the end of the study.
Glavno merilo učinkovitosti je bilo število bolnikov, ki so imeli ob koncu študije raven paratiroidnega hormona manj kot 250 mikrogramov na liter.
The main measure of effectiveness was the number of patients who had a reduction in blood calcium levels of more than 1 mg per decilitre by the time a maintenance dose had been found (between two and 16 weeks after the start of the study).
Glavno merilo učinkovitosti je bilo število bolnikov, pri katerih so se ravni kalcija v krvi zmanjšale za več kot 1 mg na deciliter do trenutka, ko je bil ugotovljen vzdrževalni odmerek (med drugim in 16. tednom po začetku študije).
The main measure of effectiveness was the number of patients who had a ‘complete response’, defined as a reduction in platelet counts of at least 50% from the start of treatment or to below 600 million/ml.
Glavno merilo učinkovitosti je bilo število bolnikov, pri katerih je bil „odziv popoln“, kar pomeni zmanjšanje števila krvnih ploščic za najmanj 50 % od začetka zdravljenja ali zmanjšanje pod 600 milijonov na mililiter.
The main measure of effectiveness was the number of patients who had an ‘event’ such as a heart attack or stroke or who died due to heart problems during the study.
Glavno merilo učinkovitosti je bilo število bolnikov, ki so med študijo utrpeli srčni napad ali kap ali umrli zaradi težav s srcem.
The main measure of effectiveness was the number of patients who had at least a 20% reduction in the number and severity of symptoms after 12 weeks of treatment.
Glavno merilo učinkovitosti je bilo število bolnikov, pri katerih je po 12 tednih zdravljenja prišlo do najmanj 20-odstotnega zmanjšanja števila in jakosti simptomov.